Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40.

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: biliary tract cancers. Version 3.2023 – November 8, 2023. 2023. https://www.nccn.org/. Accessed 19 Feb 2024.

Rushbrook SM, Kendall TJ, Zen Y, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023;73(1):16–46.

Article  PubMed  Google Scholar 

Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.

Article  PubMed  PubMed Central  Google Scholar 

Mayo Clinic. Cholangiocarcinoma (bile duct cancer). 2023. https://www.mayoclinic.org/diseases-conditions/cholangiocarcinoma/symptoms-causes/syc-20352408. Accessed 19 Feb 2024.

Javle M, King G, Spencer K, et al. Futibatinib, an irreversible FGFR1-4 inhibitor for the treatment of FGFR-aberrant tumors. Oncologist. 2023;28(11):928–43.

Article  PubMed  PubMed Central  Google Scholar 

Wekking D, Pretta A, Martella S, et al. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas. Heliyon. 2023;9(9): e19541.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taiho Pharma Netherlands B.V. Lytgobi (futibatinib) 4 mg film-coated tablets: EU summary of product characteristics. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi. Accessed 19 Feb 2024.

Taiho Oncology Inc. LYTGOBI® (futibatinib) tablets, for oral use: US prescribing information. 2022. https://www.fda.gov/. Accessed 19 Feb 2024.

Taiho Pharmaceutical Co. Ltd. LYTGOBI® (futibatinib) 4 mg tablets: Japanese prescribing information. 2023. https://www.pmda.go.jp/. Accessed 19 Feb 2024.

Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14(4):494–500.

Article  CAS  PubMed  Google Scholar 

Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80(22):4986–97.

Article  CAS  PubMed  Google Scholar 

Valery M, Vasseur D, Fachinetti F, et al. Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments. Cancers (Basel). 2023;15(18):4446.

Article  CAS  PubMed  Google Scholar 

Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cleary JM, Raghavan S, Wu Q, et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 2021;11(10):2488–505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020;31(10):1405–12.

Article  CAS  PubMed  Google Scholar 

Hollebecque A, Bridgewater JA, Meric-Bernstam F, et al. Assessment of futibatinib exposure-response (E-R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA) [abstract no. 52P]. Ann Oncol. 2021;32(Suppl 5):S378–9.

Article  Google Scholar 

Yamamiya I, Lester R, Sonnichsen D, et al. Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, QT/QTc, phase 1 study in healthy subjects. Clin Pharmacol Drug Dev. 2023;12(3):304–13.

Article  CAS  PubMed  Google Scholar 

Yamamiya I, Hunt A, Yamashita F, et al. Evaluation of potential food effects and drug interactions with lansoprazole in healthy adult volunteers receiving futibatinib. Clin Pharmacol Drug Dev. 2023;12(3):294–303.

Article  CAS  PubMed  Google Scholar 

Yamamiya I, Hunt A, Takenaka T, et al. Evaluation of the cytochrome P450 3A and p-glycoprotein drug-drug interaction potential of futibatinib. Clin Pharmacol Drug Dev. 2023;12(10):966–78.

Article  CAS  PubMed  Google Scholar 

Gao L, Yamamiya I, Pinti M, et al. A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib. Clin Transl Sci. 2023;16(9):1713–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doi T, Shitara K, Kojima T, et al. Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci. 2023;114(2):574–85.

Article  CAS  PubMed  Google Scholar 

Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–39.

Article  CAS  PubMed  Google Scholar 

Bridgewater J, Meric-Bernstam F, Hollebecque A, et al. Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: subgroup analyses of a phase II study (FOENIX-CCA2) [abstract no. 54P]. Ann Oncol. 2020;31(Suppl 4):S261–2.

Article  Google Scholar 

European Medicines Agency. Lytgobi (futibatinib): EU assessment report. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi. Accessed 19 Feb 2024.

US Food and Drug Administration. Futibatinib (Lytgobi): multi‐disciplinary review and evaluation. 2022. https://www.fda.gov/. Accessed 19 Feb 2024.

Goyal L, Meric-Bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements [abstract no. 4009]. J Clin Oncol. 2022;40(16 Suppl).

Borad MJ, Paine A, Wacheck V, et al. Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements [abstract no. 440]. J Clin Oncol. 2022;40(4 Suppl):400.

Google Scholar